# A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs

> **NCT01878318** · PHASE4 · WITHDRAWN · sponsor: **Hoffmann-La Roche**

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** methotrexate
- **DRUG:** tocilizumab [RoActemra/Actemra]

## Key facts

- **NCT ID:** NCT01878318
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-06
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01878318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01878318, "A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01878318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*